Spencer Pharmaceutical Provides Supplemental Information on $0.97 Buyout Offer
2010年11月15日 - 11:35PM
Marketwired
Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) provided its
shareholder with supplemental information on the $0.97 per share
buyout offer.
According to ongoing negotiations, the offering party has
stipulated that the Buyout was for 100% of the shares and that upon
an agreed timeline that the shares will be required to be tendered
by all shareholders. They have also stated that they reserved the
right to acquire shares in the open market prior to the closing of
the transaction. They have assured that they would place the funds
into escrow and a mutual timeline was to be established. The
objective of the offering party is to take the company private as
at the close of the transaction. The company expects to receive the
approval by the offering party to release their name and contact
information on or before November 25, 2010.
"We are moving in the right step to assure a transaction is
concluded for our shareholders," said Dr. Max Arella, President of
Spencer Pharmaceutical Inc. "We understand that there is a lot of
scientism with the planned transaction because of the
confidentiality of the buyer and we can only assure our
shareholders that we are working diligently and in good faith. The
offering party is not an American company and the cultural
differences and language sometimes require more attention," further
added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical
Research and Development Corporation, which is developing
innovative drug release and absorption systems for the treatment of
metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this
press release may be "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "anticipate," "believe," "estimate," "expect,"
"intend" and similar expressions, as they relate to the company or
its management, identify forward-looking statements. These
statements are based on current expectations, estimates and
projections about the company's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Therefore, actual
outcomes and results may, and probably will, differ materially from
what is expressed or forecasted in such forward-looking statements
due to numerous factors, including those described above. In
addition, such statements could be affected by risks and
uncertainties related to the exploration for and development of
mineralized material, product demand, market and customer
acceptance, competition, pricing and development difficulties, as
well as general industry and market conditions and growth rates and
general economic conditions. Any forward-looking statements speak
only as of the date on which they are made, and the company does
not undertake any obligation to update any forward-looking
statement to reflect events or circumstances after the date of this
release. Information on the Company's website does not constitute a
part of this release.
Contact: Dr. Max Arella President Spencer Pharmaceutical
Inc. Tel. 1+(617) 973-5017
Spencer Pharmaceutical (CE) (USOTC:SPPH)
過去 株価チャート
から 5 2024 まで 6 2024
Spencer Pharmaceutical (CE) (USOTC:SPPH)
過去 株価チャート
から 6 2023 まで 6 2024